Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Neovascular Age-related Macular Degeneration Treatment Market Snapshot (2023 to 2033)

The global neovascular age-related macular degeneration treatment market is expected to garner a market value of US$ 3 billion in 2023 and is expected to accumulate a market value of US$ 4.89 billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for neovascular age-related macular degeneration treatment registered a CAGR of 3.5% in the historical period 2018 to 2022.

The Neovascular Age-related Macular Degeneration Treatment market is a segment of the healthcare industry that deals with the effective management of the condition. The market is expected to grow significantly in the coming years due to the increasing prevalence of the condition worldwide. Neovascular age-related macular degeneration is a serious eye condition that affects older adults and can lead to vision loss. The treatment of nAMD typically involves medications that are injected into the eye to stop the growth of abnormal blood vessels in the retina. These medications are known as anti-VEGF drugs.

Report Attribute Details
Expected Market Value (2023) US$ 3 billion
Anticipated Forecast Value (2033) US$ 4.89 billion
Projected Growth Rate (2023 to 2033) 5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Neovascular Age-related Macular Degeneration Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for Neovascular Age-related Macular Degeneration Treatment reflected a value of 3.5% during the historical period, 2018 to 2022.

The neovascular age-related macular degeneration treatment market has been growing rapidly in recent years due to the increasing prevalence of nAMD and the availability of effective drugs for its treatment. The market is expected to continue growing in the coming years as the aging population continues to grow.

The key players in the neovascular age-related macular degeneration treatment market include pharmaceutical companies such as Roche, Novartis, Regeneron, and Bayer. These companies are investing heavily in research and development to bring new and improved drugs to market for the treatment of nAMD. In addition to anti-VEGF drugs, other treatments for nAMD are also being developed, including gene therapy and sustained-release drug delivery systems. These new treatments have the potential to improve patient outcomes and reduce the need for frequent injections.

Moreover, strategic collaborations, mergers and acquisitions, and product innovations are expected to further drive the growth of the Neovascular Age-related Macular Degeneration Treatment market. Key players in the market are investing in R&D activities to develop new treatment options and improve the efficacy of existing ones. The market offers growth opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers. Overall, the market for neovascular age-related macular degeneration treatment is expected to register a CAGR of 5% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Neovascular Age-related Macular Degeneration Treatment Market?

Growing Awareness along with increasing prevalence of Focal Segmental Glomerulosclerosis (FSGS) to drive growth

The neovascular age-related macular degeneration (nAMD) treatment market has been experiencing significant growth in recent years and is expected to continue growing in the coming years. Several factors are driving this growth, including:

  • Increasing prevalence of nAMD: As the global population ages, the prevalence of nAMD is increasing. According to the World Health Organization, the number of people aged 65 years and older is projected to triple by 2050, which will lead to an increase in the number of nAMD cases.
  • Advancements in treatment options: The introduction of anti-VEGF drugs has revolutionized the treatment of nAMD. These drugs have been shown to be highly effective in halting the growth of abnormal blood vessels in the retina, which can prevent vision loss in patients with nAMD.
  • Rising healthcare expenditure: As healthcare expenditure continues to rise, more resources are being allocated towards the development and adoption of new nAMD treatments. This has led to an increase in research and development activities, as well as greater patient access to new and innovative treatments.
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by the Neovascular Age-related Macular Degeneration Treatment Market?

Expensive Cost of Treatment to restrict Market Growth

The cost of nAMD treatment with anti-VEGF drugs can be very high, and this can limit patient access to these treatments. Some patients may not be able to afford the cost of treatment, while others may face limitations in their insurance coverage.

Moreover, Anti-VEGF drugs are typically administered through injections directly into the eye, which can be uncomfortable and inconvenient for patients. Additionally, these injections need to be given on a regular basis, which can be challenging for patients who have difficulty traveling to clinics or for those who may be homebound.

Region-Wise Insights

How is the Neovascular Age-related Macular Degeneration Treatment Market Turning Out in the South & East Asia Regions?

Increasing awareness and diagnosis of the condition Shaping Landscape in South & East Asia

The neovascular age-related macular degeneration (nAMD) treatment market is turning out to be promising in the South & East Asia region. The prevalence of nAMD is increasing in the region due to aging populations, changing lifestyles, and increasing prevalence of diabetes.

Several pharmaceutical companies have been focusing on expanding their market presence in the region by investing in research and development, strategic partnerships, and collaborations. For example, Novartis and Roche have been leading players in the nAMD treatment market in the region, and have been expanding their product portfolios and conducting clinical trials for new treatments.

In addition, the availability of biosimilars of anti-VEGF drugs has increased in the region, which has made treatment more affordable for patients. The use of biosimilars has also increased competition in the market, leading to more affordable treatment options. However, challenges remain in the region, including limited access to specialized ophthalmologists, inadequate healthcare infrastructure in some areas, and low awareness of nAMD and its treatment options among patients and healthcare providers.

Overall, the nAMD treatment market in South & East Asia is expected to continue growing in the coming years, driven by factors such as increasing patient awareness, expanding healthcare infrastructure, and the introduction of new treatments.

What are the Factors Boosting the Market for Neovascular Age-related Macular Degeneration Treatment in North America?

Increasing Focus on technological advancements driving demand for Neovascular Age-related Macular Degeneration Treatment in North America

The aging population in North America is contributing to the increasing prevalence of nAMD. According to the American Academy of Ophthalmology, more than 10 million Americans are affected by AMD, with nAMD accounting for a significant portion of these cases.

North America is at the forefront of research and development of new nAMD treatments, and the availability of advanced treatment options such as anti-VEGF drugs has contributed to the growth of the market. Additionally, the introduction of gene therapy and sustained-release drug delivery systems has further expanded treatment options.

The strong healthcare infrastructure in North America has contributed to the growth of the nAMD treatment market, with access to specialized ophthalmologists, well-equipped healthcare facilities, and advanced diagnostic and treatment technologies. The increasing awareness of nAMD and its treatment options among patients and healthcare providers has contributed to the growth of the market. Patients are now seeking earlier diagnosis and treatment, which has increased the demand for effective nAMD treatments.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By Disease type, Which Segment is Likely to Account for a Significant Share?

Wet AMD segment to hold a significant share and push market growth

Wet AMD is likely to account for a significant share in the Neovascular Age-related Macular Degeneration Treatment market is Wet AMD. Wet AMD is a more severe form of the disease and can progress rapidly, causing severe vision loss or blindness if left untreated.

This has led to a higher demand for treatments that can effectively manage the condition, such as anti-vascular endothelial growth factor (anti-VEGF) drugs. These drugs are used to block the growth of abnormal blood vessels and reduce fluid leakage in the retina, slowing down the progression of the disease and improving vision.

By State of Disease, Which Segment is Likely to Account for a Significant Share?

Late-stage AMD segment to hold a significant share and push market growth

Among the different stages of AMD, the Late-stage AMD segment is likely to account for a significant share in the neovascular age-related macular degeneration treatment market.

Late-stage AMD includes both wet AMD and geographic atrophy, which are advanced forms of the disease that can cause severe vision loss or blindness if left untreated. As a result, there is a higher demand for effective treatments for late-stage AMD, such as anti-vascular endothelial growth factor (anti-VEGF) drugs, which can help slow down the progression of the disease and improve vision.

Market Competition

Key players in the market include companies such as Competition Deep Dive, Competition Deep Dive, Bausch & Lomb Incorporate, Novartis AG, Pfizer Inc., ALLERGAN, Acucela Inc., Santen Pharmaceuticals Co., Ophthotech Corporation, Alimera Sciences Inc.GlaxoSmithKline PLC, Regeneron Pharmaceutical Inc., Bayer AG, Rxi Pharmaceuticals Inc. along with healthcare providers and technology companies among other global players.

  • Susvimo™ (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant was granted FDA approval on October 22, 2021. This approval is for the treatment of wet or neovascular age-related macular degeneration (AMD) in individuals who have previously responded to at least two anti-vascular endothelial growth factor (VEGF) injections. Wet AMD is a leading cause of blindness in people aged 60 and older and affects approximately 1.1 million people in the United States.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 3 billion
Market Value in 2033 US$ 4.89 billion
Growth Rate CAGR of 5% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Disease Type
  • Drug Type
  • Age group
  • Gender
  • Stage of Disease
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • F. Hoffmann- La Roche AG
  • Bausch + Lomb
  • Novartis AG
  • Pfizer Inc.
  • Allergan Plc.
  • Acucela Inc.
  • Santen Pharmaceuticals Co.
  • Ophthotech Corporation
  • Alimera Sciences Inc.
  • GSK plc.
  • Regeneron Pharmaceuticals Inc.
  • Bayer AG
  • RXi Pharmaceuticals Inc.
Customization Available Upon Request

Key Segments Profiled in the Neovascular Age-related Macular Degeneration Treatment Industry Survey

Drug Type:

  • Ranibizumab
  • Aflibercept
  • Bevacizumab
  • Brolucizumab
  • Faricimab

Disease Type:

  • Dry AMD
  • Wet AMD

Age Group:

  • Less than 60
  • Between 60 to 80
  • More than 80

Gender:

  • Male
  • Female

Stage of Disease:

  • Early-stage AMD
  • Intermediate AMD
  • Late-stage AMD

Distribution Channel:

  • Hospital Pharmacy
  • Specialty Pharmacy
  • Online Pharmacy

Region:North America

  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Neovascular Age-related Macular Degeneration Treatment Market Size?

The neovascular age-related macular degeneration treatment market size reaches US$ 3 billion in 2023.

What Size is the Neovascular Age-related Macular Degeneration Treatment Market Expected to Reach by 2033?

The market is set to surge at a 5% CAGR, reaching a valuation of US$ 4.89 billion by 2033.

How has the Market Evolved During the Historical Period?

The market witnessed a 3.5% CAGR between 2018 and 2022.

Which Country Shows Promising Potential for Neovascular Age-related Macular Degeneration Treatment?

The United States exhibits promising potential for neovascular age-related macular degeneration treatment due to its advanced healthcare infrastructure.

Which Disease Type Segment Generates the Maximum Revenue in the Market?

The Wet AMD segment demonstrates significant expansion in the neovascular age-related macular degeneration treatment market.

Table of Content

1. Executive Summary | Neovascular Age-related Macular Degeneration Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033

        5.3.1. Ranibizumab

        5.3.2. Aflibercept

        5.3.3. Bevacizumab

        5.3.4. Brolucizumab

        5.3.5. Faricimab

    5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033

        6.3.1. Dry AMD

        6.3.2. Wet AMD

    6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Age Group 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Age Group , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Age Group , 2023 to 2033

        7.3.1. Less Than 60

        7.3.2. Between 60 to 80

        7.3.3. More Than 80

    7.4. Y-o-Y Growth Trend Analysis By Age Group , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Age Group , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Gender

    8.1. Introduction / Key Findings

    8.2. Historical Market Size Value (US$ Million) Analysis By Gender, 2018 to 2022

    8.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Gender, 2023 to 2033

        8.3.1. Male

        8.3.2. Female

    8.4. Y-o-Y Growth Trend Analysis By Gender, 2018 to 2022

    8.5. Absolute $ Opportunity Analysis By Gender, 2023 to 2033

9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Stage of Disease

    9.1. Introduction / Key Findings

    9.2. Historical Market Size Value (US$ Million) Analysis By Stage of Disease, 2018 to 2022

    9.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Stage of Disease, 2023 to 2033

        9.3.1. Early-stage AMD

        9.3.2. Intermediate AMD

        9.3.3. Late-stage AMD

    9.4. Y-o-Y Growth Trend Analysis By Stage of Disease, 2018 to 2022

    9.5. Absolute $ Opportunity Analysis By Stage of Disease, 2023 to 2033

10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    10.1. Introduction / Key Findings

    10.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    10.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        10.3.1. Hospital Pharmacy

        10.3.2. Specialty Pharmacy

        10.3.3. Online Pharmacy

    10.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    10.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    11.1. Introduction

    11.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    11.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        11.3.1. North America

        11.3.2. Latin America

        11.3.3. Europe

        11.3.4. South Asia

        11.3.5. East Asia

        11.3.6. Oceania

        11.3.7. MEA

    11.4. Market Attractiveness Analysis By Region

12. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. United States

            12.2.1.2. Canada

        12.2.2. By Drug Type

        12.2.3. By Disease Type

        12.2.4. By Age Group

        12.2.5. By Gender

        12.2.6. By Stage of Disease

        12.2.7. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Type

        12.3.3. By Disease Type

        12.3.4. By Age Group

        12.3.5. By Gender

        12.3.6. By Stage of Disease

        12.3.7. By Distribution Channel

    12.4. Key Takeaways

13. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Brazil

            13.2.1.2. Mexico

            13.2.1.3. Rest of Latin America

        13.2.2. By Drug Type

        13.2.3. By Disease Type

        13.2.4. By Age Group

        13.2.5. By Gender

        13.2.6. By Stage of Disease

        13.2.7. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Type

        13.3.3. By Disease Type

        13.3.4. By Age Group

        13.3.5. By Gender

        13.3.6. By Stage of Disease

        13.3.7. By Distribution Channel

    13.4. Key Takeaways

14. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Germany

            14.2.1.2. United Kingdom

            14.2.1.3. France

            14.2.1.4. Spain

            14.2.1.5. Italy

            14.2.1.6. Rest of Europe

        14.2.2. By Drug Type

        14.2.3. By Disease Type

        14.2.4. By Age Group

        14.2.5. By Gender

        14.2.6. By Stage of Disease

        14.2.7. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Drug Type

        14.3.3. By Disease Type

        14.3.4. By Age Group

        14.3.5. By Gender

        14.3.6. By Stage of Disease

        14.3.7. By Distribution Channel

    14.4. Key Takeaways

15. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. India

            15.2.1.2. Malaysia

            15.2.1.3. Singapore

            15.2.1.4. Thailand

            15.2.1.5. Rest of South Asia

        15.2.2. By Drug Type

        15.2.3. By Disease Type

        15.2.4. By Age Group

        15.2.5. By Gender

        15.2.6. By Stage of Disease

        15.2.7. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Drug Type

        15.3.3. By Disease Type

        15.3.4. By Age Group

        15.3.5. By Gender

        15.3.6. By Stage of Disease

        15.3.7. By Distribution Channel

    15.4. Key Takeaways

16. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    16.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    16.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        16.2.1. By Country

            16.2.1.1. China

            16.2.1.2. Japan

            16.2.1.3. South Korea

        16.2.2. By Drug Type

        16.2.3. By Disease Type

        16.2.4. By Age Group

        16.2.5. By Gender

        16.2.6. By Stage of Disease

        16.2.7. By Distribution Channel

    16.3. Market Attractiveness Analysis

        16.3.1. By Country

        16.3.2. By Drug Type

        16.3.3. By Disease Type

        16.3.4. By Age Group

        16.3.5. By Gender

        16.3.6. By Stage of Disease

        16.3.7. By Distribution Channel

    16.4. Key Takeaways

17. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    17.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    17.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        17.2.1. By Country

            17.2.1.1. Australia

            17.2.1.2. New Zealand

        17.2.2. By Drug Type

        17.2.3. By Disease Type

        17.2.4. By Age Group

        17.2.5. By Gender

        17.2.6. By Stage of Disease

        17.2.7. By Distribution Channel

    17.3. Market Attractiveness Analysis

        17.3.1. By Country

        17.3.2. By Drug Type

        17.3.3. By Disease Type

        17.3.4. By Age Group

        17.3.5. By Gender

        17.3.6. By Stage of Disease

        17.3.7. By Distribution Channel

    17.4. Key Takeaways

18. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    18.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    18.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        18.2.1. By Country

            18.2.1.1. GCC Countries

            18.2.1.2. South Africa

            18.2.1.3. Israel

            18.2.1.4. Rest of MEA

        18.2.2. By Drug Type

        18.2.3. By Disease Type

        18.2.4. By Age Group

        18.2.5. By Gender

        18.2.6. By Stage of Disease

        18.2.7. By Distribution Channel

    18.3. Market Attractiveness Analysis

        18.3.1. By Country

        18.3.2. By Drug Type

        18.3.3. By Disease Type

        18.3.4. By Age Group

        18.3.5. By Gender

        18.3.6. By Stage of Disease

        18.3.7. By Distribution Channel

    18.4. Key Takeaways

19. Key Countries Market Analysis

    19.1. U.S.

        19.1.1. Pricing Analysis

        19.1.2. Market Share Analysis, 2022

            19.1.2.1. By Drug Type

            19.1.2.2. By Disease Type

            19.1.2.3. By Age Group

            19.1.2.4. By Gender

            19.1.2.5. By Stage of Disease

            19.1.2.6. By Distribution Channel

    19.2. Canada

        19.2.1. Pricing Analysis

        19.2.2. Market Share Analysis, 2022

            19.2.2.1. By Drug Type

            19.2.2.2. By Disease Type

            19.2.2.3. By Age Group

            19.2.2.4. By Gender

            19.2.2.5. By Stage of Disease

            19.2.2.6. By Distribution Channel

    19.3. Brazil

        19.3.1. Pricing Analysis

        19.3.2. Market Share Analysis, 2022

            19.3.2.1. By Drug Type

            19.3.2.2. By Disease Type

            19.3.2.3. By Age Group

            19.3.2.4. By Gender

            19.3.2.5. By Stage of Disease

            19.3.2.6. By Distribution Channel

    19.4. Mexico

        19.4.1. Pricing Analysis

        19.4.2. Market Share Analysis, 2022

            19.4.2.1. By Drug Type

            19.4.2.2. By Disease Type

            19.4.2.3. By Age Group

            19.4.2.4. By Gender

            19.4.2.5. By Stage of Disease

            19.4.2.6. By Distribution Channel

    19.5. Germany

        19.5.1. Pricing Analysis

        19.5.2. Market Share Analysis, 2022

            19.5.2.1. By Drug Type

            19.5.2.2. By Disease Type

            19.5.2.3. By Age Group

            19.5.2.4. By Gender

            19.5.2.5. By Stage of Disease

            19.5.2.6. By Distribution Channel

    19.6. U.K.

        19.6.1. Pricing Analysis

        19.6.2. Market Share Analysis, 2022

            19.6.2.1. By Drug Type

            19.6.2.2. By Disease Type

            19.6.2.3. By Age Group 

            19.6.2.4. By Gender

            19.6.2.5. By Stage of Disease

            19.6.2.6. By Distribution Channel

    19.7. France

        19.7.1. Pricing Analysis

        19.7.2. Market Share Analysis, 2022

            19.7.2.1. By Drug Type

            19.7.2.2. By Disease Type

            19.7.2.3. By Age Group 

            19.7.2.4. By Gender

            19.7.2.5. By Stage of Disease

            19.7.2.6. By Distribution Channel

    19.8. Spain

        19.8.1. Pricing Analysis

        19.8.2. Market Share Analysis, 2022

            19.8.2.1. By Drug Type

            19.8.2.2. By Disease Type

            19.8.2.3. By Age Group 

            19.8.2.4. By Gender

            19.8.2.5. By Stage of Disease

            19.8.2.6. By Distribution Channel

    19.9. Italy

        19.9.1. Pricing Analysis

        19.9.2. Market Share Analysis, 2022

            19.9.2.1. By Drug Type

            19.9.2.2. By Disease Type

            19.9.2.3. By Age Group 

            19.9.2.4. By Gender

            19.9.2.5. By Stage of Disease

            19.9.2.6. By Distribution Channel

    19.10. India

        19.10.1. Pricing Analysis

        19.10.2. Market Share Analysis, 2022

            19.10.2.1. By Drug Type

            19.10.2.2. By Disease Type

            19.10.2.3. By Age Group 

            19.10.2.4. By Gender

            19.10.2.5. By Stage of Disease

            19.10.2.6. By Distribution Channel

    19.11. Malaysia

        19.11.1. Pricing Analysis

        19.11.2. Market Share Analysis, 2022

            19.11.2.1. By Drug Type

            19.11.2.2. By Disease Type

            19.11.2.3. By Age Group 

            19.11.2.4. By Gender

            19.11.2.5. By Stage of Disease

            19.11.2.6. By Distribution Channel

    19.12. Singapore

        19.12.1. Pricing Analysis

        19.12.2. Market Share Analysis, 2022

            19.12.2.1. By Drug Type

            19.12.2.2. By Disease Type

            19.12.2.3. By Age Group 

            19.12.2.4. By Gender

            19.12.2.5. By Stage of Disease

            19.12.2.6. By Distribution Channel

    19.13. Thailand

        19.13.1. Pricing Analysis

        19.13.2. Market Share Analysis, 2022

            19.13.2.1. By Drug Type

            19.13.2.2. By Disease Type

            19.13.2.3. By Age Group 

            19.13.2.4. By Gender

            19.13.2.5. By Stage of Disease

            19.13.2.6. By Distribution Channel

    19.14. China

        19.14.1. Pricing Analysis

        19.14.2. Market Share Analysis, 2022

            19.14.2.1. By Drug Type

            19.14.2.2. By Disease Type

            19.14.2.3. By Age Group 

            19.14.2.4. By Gender

            19.14.2.5. By Stage of Disease

            19.14.2.6. By Distribution Channel

    19.15. Japan

        19.15.1. Pricing Analysis

        19.15.2. Market Share Analysis, 2022

            19.15.2.1. By Drug Type

            19.15.2.2. By Disease Type

            19.15.2.3. By Age Group 

            19.15.2.4. By Gender

            19.15.2.5. By Stage of Disease

            19.15.2.6. By Distribution Channel

    19.16. South Korea

        19.16.1. Pricing Analysis

        19.16.2. Market Share Analysis, 2022

            19.16.2.1. By Drug Type

            19.16.2.2. By Disease Type

            19.16.2.3. By Age Group 

            19.16.2.4. By Gender

            19.16.2.5. By Stage of Disease

            19.16.2.6. By Distribution Channel

    19.17. Australia

        19.17.1. Pricing Analysis

        19.17.2. Market Share Analysis, 2022

            19.17.2.1. By Drug Type

            19.17.2.2. By Disease Type

            19.17.2.3. By Age Group 

            19.17.2.4. By Gender

            19.17.2.5. By Stage of Disease

            19.17.2.6. By Distribution Channel

    19.18. New Zealand

        19.18.1. Pricing Analysis

        19.18.2. Market Share Analysis, 2022

            19.18.2.1. By Drug Type

            19.18.2.2. By Disease Type

            19.18.2.3. By Age Group 

            19.18.2.4. By Gender

            19.18.2.5. By Stage of Disease

            19.18.2.6. By Distribution Channel

    19.19. GCC Countries

        19.19.1. Pricing Analysis

        19.19.2. Market Share Analysis, 2022

            19.19.2.1. By Drug Type

            19.19.2.2. By Disease Type

            19.19.2.3. By Age Group 

            19.19.2.4. By Gender

            19.19.2.5. By Stage of Disease

            19.19.2.6. By Distribution Channel

    19.20. South Africa

        19.20.1. Pricing Analysis

        19.20.2. Market Share Analysis, 2022

            19.20.2.1. By Drug Type

            19.20.2.2. By Disease Type

            19.20.2.3. By Age Group 

            19.20.2.4. By Gender

            19.20.2.5. By Stage of Disease

            19.20.2.6. By Distribution Channel

    19.21. Israel

        19.21.1. Pricing Analysis

        19.21.2. Market Share Analysis, 2022

            19.21.2.1. By Drug Type

            19.21.2.2. By Disease Type

            19.21.2.3. By Age Group 

            19.21.2.4. By Gender

            19.21.2.5. By Stage of Disease

            19.21.2.6. By Distribution Channel

20. Market Structure Analysis

    20.1. Competition Dashboard

    20.2. Competition Benchmarking

    20.3. Market Share Analysis of Top Players

        20.3.1. By Regional

        20.3.2. By Drug Type

        20.3.3. By Disease Type

        20.3.4. By Age Group 

        20.3.5. By Gender

        20.3.6. By Stage of Disease

        20.3.7. By Distribution Channel

21. Competition Analysis

    21.1. Competition Deep Dive

        21.1.1. F.Hoffmann-La Roche AG

            21.1.1.1. Overview

            21.1.1.2. Product Portfolio

            21.1.1.3. Profitability by Market Segments

            21.1.1.4. Sales Footprint

            21.1.1.5. Strategy Overview

                21.1.1.5.1. Marketing Strategy

        21.1.2. Bausch + Lomb

            21.1.2.1. Overview

            21.1.2.2. Product Portfolio

            21.1.2.3. Profitability by Market Segments

            21.1.2.4. Sales Footprint

            21.1.2.5. Strategy Overview

                21.1.2.5.1. Marketing Strategy

        21.1.3. Novartis AG

            21.1.3.1. Overview

            21.1.3.2. Product Portfolio

            21.1.3.3. Profitability by Market Segments

            21.1.3.4. Sales Footprint

            21.1.3.5. Strategy Overview

                21.1.3.5.1. Marketing Strategy

        21.1.4. Pfizer Inc.

            21.1.4.1. Overview

            21.1.4.2. Product Portfolio

            21.1.4.3. Profitability by Market Segments

            21.1.4.4. Sales Footprint

            21.1.4.5. Strategy Overview

                21.1.4.5.1. Marketing Strategy

        21.1.5. Allergan Plc.

            21.1.5.1. Overview

            21.1.5.2. Product Portfolio

            21.1.5.3. Profitability by Market Segments

            21.1.5.4. Sales Footprint

            21.1.5.5. Strategy Overview

                21.1.5.5.1. Marketing Strategy

        21.1.6. Acucela Inc.

            21.1.6.1. Overview

            21.1.6.2. Product Portfolio

            21.1.6.3. Profitability by Market Segments

            21.1.6.4. Sales Footprint

            21.1.6.5. Strategy Overview

                21.1.6.5.1. Marketing Strategy

        21.1.7. Santen Pharmaceuticals Co.

            21.1.7.1. Overview

            21.1.7.2. Product Portfolio

            21.1.7.3. Profitability by Market Segments

            21.1.7.4. Sales Footprint

            21.1.7.5. Strategy Overview

                21.1.7.5.1. Marketing Strategy

        21.1.8. Ophthotech Corporation

            21.1.8.1. Overview

            21.1.8.2. Product Portfolio

            21.1.8.3. Profitability by Market Segments

            21.1.8.4. Sales Footprint

            21.1.8.5. Strategy Overview

                21.1.8.5.1. Marketing Strategy

        21.1.9. Alimera Sciences Inc.

            21.1.9.1. Overview

            21.1.9.2. Product Portfolio

            21.1.9.3. Profitability by Market Segments

            21.1.9.4. Sales Footprint

            21.1.9.5. Strategy Overview

                21.1.9.5.1. Marketing Strategy

        21.1.10. GSK plc.

            21.1.10.1. Overview

            21.1.10.2. Product Portfolio

            21.1.10.3. Profitability by Market Segments

            21.1.10.4. Sales Footprint

            21.1.10.5. Strategy Overview

                21.1.10.5.1. Marketing Strategy

        21.1.11. Regeneron Pharmaceuticals Inc.

            21.1.11.1. Overview

            21.1.11.2. Product Portfolio

            21.1.11.3. Profitability by Market Segments

            21.1.11.4. Sales Footprint

            21.1.11.5. Strategy Overview

                21.1.11.5.1. Marketing Strategy

        21.1.12. Bayer AG

            21.1.12.1. Overview

            21.1.12.2. Product Portfolio

            21.1.12.3. Profitability by Market Segments

            21.1.12.4. Sales Footprint

            21.1.12.5. Strategy Overview

                21.1.12.5.1. Marketing Strategy

        21.1.13. RXi Pharmaceuticals Inc.

            21.1.13.1. Overview

            21.1.13.2. Product Portfolio

            21.1.13.3. Profitability by Market Segments

            21.1.13.4. Sales Footprint

            21.1.13.5. Strategy Overview

                21.1.13.5.1. Marketing Strategy

22. Assumptions & Acronyms Used

23. Research Methodology

Recommendations

Healthcare

Vision Care Market

Published : August 2023

Healthcare

Age Related Vision Dysfunction Market

Published : December 2022

Healthcare

Age Related Molecular Degeneration Market

Published : December 2022

Healthcare

Vision Screeners Market

Published : July 2022

Explore Healthcare Insights

View Reports

Neovascular Age-related Macular Degeneration Treatment Market